Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 8604
TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247411(US9453018, 353 | US10336754, Example 353 | US11053...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247414(US9453018, 368 | US9453018, 367 | US10336754, Exam...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247416(US9453018, 369 | US10336754, Example 369 | US11053...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US9453018, 371 | US9453018, 370 | US10336754, Exam...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US9453018, 371 | US9453018, 370 | US10336754, Exam...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247414(US9453018, 368 | US9453018, 367 | US10336754, Exam...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247418(US9453018, 372 | US10336754, Example 372 | US11053...)
Affinity DataKi:  0.200nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247419(US9453018, 373 | US10336754, Example 373 | US11053...)
Affinity DataKi:  0.200nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247413(US9453018, 363 | US9453018, 362 | US10336754, Exam...)
Affinity DataKi:  0.200nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247413(US9453018, 363 | US9453018, 362 | US10336754, Exam...)
Affinity DataKi:  0.200nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247412(US9453018, 354 | US10336754, Example 354 | US11053...)
Affinity DataKi:  0.600nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247412(US9453018, 354 | US10336754, Example 354 | US11053...)
Affinity DataKi:  10nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US9453018, 371 | US9453018, 370 | US10336754, Exam...)
Affinity DataKi:  17nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US9453018, 371 | US9453018, 370 | US10336754, Exam...)
Affinity DataKi:  19nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247413(US9453018, 363 | US9453018, 362 | US10336754, Exam...)
Affinity DataKi:  22nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247413(US9453018, 363 | US9453018, 362 | US10336754, Exam...)
Affinity DataKi:  23nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247414(US9453018, 368 | US9453018, 367 | US10336754, Exam...)
Affinity DataKi:  24nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247411(US9453018, 353 | US10336754, Example 353 | US11053...)
Affinity DataKi:  28nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247414(US9453018, 368 | US9453018, 367 | US10336754, Exam...)
Affinity DataKi:  32nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247416(US9453018, 369 | US10336754, Example 369 | US11053...)
Affinity DataKi:  33nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247418(US9453018, 372 | US10336754, Example 372 | US11053...)
Affinity DataKi:  35nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247419(US9453018, 373 | US10336754, Example 373 | US11053...)
Affinity DataKi:  37nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
US Patent